Maligne B-Zell-Lymphome: Fortschritte in der Therapie des follikulären Lymphoms und des Mantelzell-Lymphoms^[*]

Prof. Dr. Wolfgang Hiddemann hat seit der Gründung der „Deutschen Studiengruppen für niedrigmaligne Lymphome“ (www.glsg.de) im Jahr 1988 die Lymphomforschung national und international maßgeblich beeinflusst und neue Standards in der Therapie der Lymphome gesetzt. Der vorliegende, ihm gewidmete Beitrag, fasst die Fortschritte auf dem Gebiet der malignen B-Zell-Lymphome am Beispiel des follikulären Lymphoms (FL) und des Mantelzell-Lymphoms (MZL) zusammen.

Schlüsselwörter

B-Zell-Lymphome - follikuläres Lymphom - Mantelzell-Lymphom - Rituximab

Key words

B-cell lymphoma - follicular lymphoma - mantle-cell lymphoma - Rituximab

• Literatur

• 1 Solal-Celigny P, Roy P, Colombat P. et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258-1265
• 2 Buske C, Hoster E, Dreyling M. et al. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 2006; 108: 1504-1508
• 3 Federico M, Bellei M, Marcheselli L. et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009; 27: 4555-4562
• 4 Pastore A, Jurinovic V, Kridel R. et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol 2015; 16: 1111-1122
• 5 Jurinovic V, Kridel R, Staiger AM. et al. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood 2016; 128: 1112-1120
• 6 Rummel MJ, Niederle N, Maschmeyer G. et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381: 1203-1210
• 7 Flinn IW, van der Jagt R, Kahl BS. et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 2014; 123: 2944-2952
• 8 Marcus R, Davies A, Ando K. et al. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. N Engl J Med 2017; 377: 1331-1344
• 9 Hiddemann W, Cheson BD. How we manage follicular lymphoma. Leukemia 2014; 28: 1388-1395
• 10 Morton LM, Wang SS, Devesa SS. et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 2006; 107: 265-276
• 11 Fowler NH, Davis RE, Rawal S. et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol 2014; 15: 1311-1318
• 12 Gopal AK, Kahl BS, de Vos S. et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014; 370: 1008-1018
• 13 Advani RH, Buggy JJ, Sharman JP. et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013; 31: 88-94
• 14 Lesokhin AM, Ansell SM, Armand P. et al. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. J Clin Oncol 2016; 34: 2698-2704
• 15 Davids MS, Roberts AW, Seymour JF. et al. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. J Clin Oncol 2017; 35: 826-833
• 16 Pastore A, Jurinovic V, Kridel R. et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol 2015; 16: 1111-1122
• 17 Dreyling M, Campo E, Hermine O. et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28 (04) iv62-iv71
• 18 Hoster E, Rosenwald A, Berger F. et al. Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. J Clin Oncol 2016; 34: 1386-1394
• 19 Schulz H, Bohlius JF, Trelle S. et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007; 99: 706-714
• 20 Kluin-Nelemans HC, Hoster E, Hermine O. et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012; 367: 520-531
• 21 Rummel MJ, Niederle N, Maschmeyer G. et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphoma. Lancet 2013; 381: 1203-1210
• 22 Hermine O, Hoster E, Walewski J. et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger). Lancet 2016; 388: 565-575
• 23 Dreyling M, Lenz G, Hoster E. et al. Early Consolidation by Myeloablative Radiochemotherapy followed by Autologous Stem Cell Transplantation in First Remission significantly prolongs Progression-Free Survival in Mantle Cell Lymphoma. Blood 2005; 105: 2677-2684
• 24 Zoellner AK, Fritsch S, Prevalsek D. et al. Sequential therapy combining clofarabine and T-cell-replete HLA-haploidentical haematopoietic SCT is feasible and shows efficacy in the treatment of refractory or relapsed aggressive lymphoma. Bone Marrow Transplant 2015; 50: 679-684
• 25 Dreyling M, Jurczak W, Jerkeman M. et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma. Lancet 2016; 387: 770-778
• 26 Trneny M, Lamy T, Walewski J. et al. Lenalidomide versus investigator’s choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT). Lancet Oncol 2016; 17: 319-331
• 27 Hess G, Herbrecht R, Romaguera J. et al. Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27: 3822-3829
• 28 Robak T, Huang H, Jin J. et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med 2015; 372: 944-953
• 29 Hiddemann W, Kneba M, Dreyling M. et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106 (12) 3725-3732